Researcher Spotlight: Pamela Allen, MD Emory University/Winship Cancer Institute Patients with advanced-stage cutaneous T-cell lymphoma (CTCL) have a median survival of fewer than five years and often experience debilitating itchy red skin. Patients with CTCL may be treated with extracorporeal…
Researcher Spotlight: Paolo Strati, MD The University of Texas Macrophages are large white blood cells that present antigens within the human immune system, an important step in signaling the immune system to attack disease,. Researchers are developing therapies which help increase the activity…
Researcher Spotlight: Reid Merryman, MD Dana-Farber Cancer Institute Marginal zone lymphoma (MZL) is a slow-growing B-cell NHL that has a relatively low number of new diagnoses each year. As a result, few clinical trials are available for MZL patients, including…
Researcher Spotlight: Rahul Lakhotia, MBBS National Institutes of Health Indolent lymphomas frequently require multiple lines of treatment as the disease recurs; the frequency of treatment makes it important to balance efficacy with potential toxicities (side effects). Dr. Lakhotia’s LCRMP project tests a new…
Researcher Spotlight: Manali Kamdar, MBBS University of Colorado Patients with indolent (slow-growing) lymphomas such as follicular (FL) or marginal zone (MZL) are chronic, frequently relapsing diseases which can vary widely in clinical presentation. Therapies are varied and can often include…
Researcher Spotlight: Andrew Ip, MD Winship Cancer Institute For many lymphoma subtypes, a bone marrow transplant is the recommended treatment strategy following relapse. Previous research has also suggested that lymphoma patients who engage in physical activity during their treatment have better outcomes. However, no…
Researcher Spotlight: Brian Hess, MD Medical University of South Carolina A common treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by an autologous stem cell transplant (a transplant of a patient’s own healthy cells).…
Researcher Spotlight: Raghuveer Ranganathan, MD University of North Carolina, Chapel Hill Though CAR T-cell therapy has been successful for many patients with Non-Hodgkin lymphomas, the nature of the two versions currently approved by the FDA can have some severe side…
Researcher Spotlight: Anita J. Kumar, MD, MSCE Tufts Medical Center For most Hodgkin lymphoma (HL) patients, chemotherapy is the standard treatment. However, patients often have their initial treatment plan modified (through dose adjustment or delays in treatment) due to concerns…
Researcher Spotlight: Jean L. Koff, MD, MS Winship Cancer Institute Post-transplant lymphoproliferative disorder (PTLD) is a type of lymphoma that may occur in patients who have undergone stem cell or organ transplants. While some PTLD patients are cured simply with…
